Gero (company)
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2018 |
| Headquarters | Singapore |
| Website | gero.ai |
Gero is a privately held biotechnology company that applies AI and ML methods to research on aging and age-related diseases. The company focuses on computational analysis of large-scale human health data to identify potential biological targets for drug discovery. Gero operates primarily at the preclinical research stage.[1][2]
History
Gero was founded in 2018 and emerged amid growing interest in the application of AI to biomedical research and drug discovery.[3] According to industry reporting, the company develops computational models intended to analyze aging-related disease processes using longitudinal human data rather than relying solely on traditional animal models.[4]
In October 2023, Gero raised $6 million in a Series A extension funding round.[5][6] Independent biotechnology industry publications reported that the funding was intended to support expansion of the company's AI platform and its research into aging and age-related diseases.[7]
Research and technology
Gero's research platform integrates ML, physics-informed modeling, and longitudinal human health datasets to study biological processes associated with aging and chronic disease.[8][9]
The company's work focuses on identifying disease-associated biological pathways and potential therapeutic targets. As of the mid-2020s, Gero's research programs were reported to be in early discovery or preclinical stages.[10]
Collaborations
Pfizer collaboration
In January 2023, Gero entered into a research collaboration with Pfizer to apply its computational platform to the identification of potential therapeutic targets for fibrotic diseases.[11] The collaboration was reported by the company and referenced in industry discussions regarding AI-driven drug discovery partnerships.[12]
Chugai Pharmaceutical (Roche Group) partnership
In July 2025, Gero entered into a joint research and license agreement with Chugai Pharmaceutical Co., Ltd., a Japanese pharmaceutical company majority owned by Roche.[13] The agreement focused on the development of antibody-based therapies for age-related diseases and included potential milestone and royalty payments of up to $250 million.[14]
Reception
Gero has been covered by biotechnology and longevity-focused industry publications in the context of broader investment and research trends involving artificial intelligence and aging science. Commentators have cited the company's funding activity and pharmaceutical collaborations as examples of increasing interest in AI-assisted approaches to drug discovery for age-related conditions.[15]
References
- ^ "Gero appoints longevity expert Dr. Brian Kennedy to board of directors". Yahoo Finance. 2025-07-14. Retrieved 2026-02-05.
- ^ "Chugai and Gero Enter Into Research and License Agreement". Lifespan.io. 2025-07-09. Retrieved 2026-02-05.
- ^ "9 Anti-Aging and Longevity Startups to Watch in 2026". WeWillCure. 2025. Retrieved 2026-02-05.
- ^ "Longevity AI biotech Gero raises $6M in Series A round for aging research". BioWorld. 2023. Retrieved 2026-02-05.
- ^ "Physics-powered GenAI biotech Gero raises $6M to find root causes of aging and age-related diseases". BioSpace. 2023. Retrieved 2026-02-05.
- ^ "Gero raises $6 million to find root causes of aging and age-related diseases". Longevity.Technology. 2023. Retrieved 2026-02-05.
- ^ "Biotech company Gero secures $6m Series extension round". Startups Magazine. 2023. Retrieved 2026-02-05.
- ^ "Longevity biotech startup Gero demonstrates the power of quantum computing in drug design". EurekAlert!. 2023-07-13. Retrieved 2026-02-05.
- ^ "AI-driven aging model lands potential multibillion-dollar runway". Longevity.Technology. 2025. Retrieved 2026-02-05.
- ^ "Longevity biotech companies GERO and FOXO Technologies to embark on joint initiative on artificial intelligence and epigenetic data to discover signatures of human health trajectories". BioSpace. 2023-08-07. Retrieved 2026-02-05.
- ^ "Pfizer and Gero Form Collaboration to Discover Potential Targets for Fibrotic Diseases". Pharmaceutical Technology. 2023-01-18. Retrieved 2026-02-05.
- ^ "Longevity biotech Gero entered a research collaboration with Pfizer" (Press release). Gero. 2023. Retrieved 2026-02-05.
- ^ "Chugai and Gero ink $250M deal to develop new therapies for age-related diseases". BioSpectrum Asia. 2025-07-09. Retrieved 2026-02-05.
- ^ "Roche's Chugai inks $250M Gero deal to access age-related disease targets". Fierce Biotech. 2025. Retrieved 2026-02-05.
- ^ "Gero Secures $6M to Unlock Aging's Secrets with Physics-Powered GenAI Biotech". BioPharmaBoardroom. 2023-10-19. Retrieved 2026-02-05.